PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of bmjBMJ helping doctors make better decisionsSearch bmj.comLatest content
 
BMJ. Jan 20, 2001; 322(7279): 134–137.
PMCID: PMC26589
Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study
R Schellenberg, senior consultant for the study group
Institute for Health Care and Science, 35625 Hüttenberg, Germany
Contributed by
Contributors: E Schrader, Pohlheim, was the study coordinator. The investigators were R Schellenberg (Hüttenberg), G Kunze (Rottweil), E R Pfaff (Mörfelden), A Massing (Offenbach), H Wältner (Albstadt-Tailfingen), Dr M Kirschbaum (Universitäts-Frauenklinik Giessen), R H Boedecker (statistics, Giessen). J Dudeck (statistics, Giessen) was responsible for statistics and data management. RS is guarantor.
Correspondence to: rued.schellenberg.med/at/t-online.de
Accepted November 17, 2000.
Objectives
To compare the efficacy and tolerability of agnus castus fruit (Vitex agnus castus L extract Ze 440) with placebo for women with the premenstrual syndrome.
Design
Randomised, double blind, placebo controlled, parallel group comparison over three menstrual cycles.
Setting
General medicine community clinics.
Participants
178 women were screened and 170 were evaluated (active 86; placebo 84). Mean age was 36 years, mean cycle length was 28 days, mean duration of menses was 4.5 days.
Interventions
Agnus castus (dry extract tablets) one tablet daily or matching placebo, given for three consecutive cycles.
Main outcome measures
Main efficacy variable: change from baseline to end point (end of third cycle) in women's self assessment of irritability, mood alteration, anger, headache, breast fullness, and other menstrual symptoms including bloating. Secondary efficacy variables: changes in clinical global impression (severity of condition, global improvement, and risk or benefit) and responder rate (50% reduction in symptoms).
Results
Improvement in the main variable was greater in the active group compared with placebo group (P<0.001). Analysis of the secondary variables showed significant (P<0.001) superiority of active treatment in each of the three global impression items. Responder rates were 52% and 24% for active and placebo, respectively. Seven women reported mild adverse events (four active; three placebo), none of which caused discontinuation of treatment.
Conclusions
Dry extract of agnus castus fruit is an effective and well tolerated treatment for the relief of symptoms of the premenstrual syndrome.
The premenstrual syndrome is a complex combination of psychological symptoms, including irritability, aggression, tension, anxiety, and depression, and somatic changes such as fluid retention, breast tenderness, headache, feeling of bloating, and weight increase.1 Women are affected irrespective of socioeconomic status, race, or cultural background, and family clusters are well documented. 2,3 The causes of the premenstrual syndrome have not been clearly elucidated4 but have been attributed to hormonal change, neurotransmitters, prostaglandins, diet, drugs, and lifestyle, so causal treatment is difficult.3
The fruits of Vitex agnus castus (the chaste tree) contain a mixture of iridoids and flavonoids, and some compounds similar in structure to the sex hormones have been isolated from the leaves and flowers.5 The effects of agnus castus have been described as similar to those of the corpus luteum.6,7 The mechanism of action may also be related to modulation of stress induced prolactin secretion via dopamine, without directly affecting luteinising hormone or follicle stimulating hormone.815 Binding to opioid receptors,16 β endorphins,17 and neuroactive flavonoids18,19 may also have a role. The plant has been used traditionally to relieve the symptoms of the premenstrual syndrome, although systematic evaluation of its efficacy is relatively recent.2 8,2022
We evaluated the effects of agnus castus fruit (Ze 440) in a large, prospective, randomised, placebo controlled study over three consecutive menstrual cycles. The study and analysis were planned and conducted under strict methodology.
Recruitment and blinding
All women were outpatients attending six general medicine clinics from April to December 1998. All physicians were experienced in the use the instruments of assessment and underwent training before the study on the scales to enhance consistency within and between centres. In each clinic all assessments were made by the same individual.
Study medication consisted of either active (fruit extract ZE 440: 60% ethanol m/m, extract ratio 6-12:1; standardised for casticin; one 20 mg tablet once daily) or placebo (matched for appearance, size, colour, taste, and smell).
The study was performed according to current European Union and International Conference on Harmonisation guidelines on Good Clinical Practice and the Declaration of Helsinki and was approved by the ethics committees of the Hessen and Baden-Württemberg Regional Orders of Physicians.
Selection of participants
All women were aged [gt-or-equal, slanted]18 years, had the premenstrual syndrome diagnosed according to the Diagnostic and Statistical Manual of Mental Disorders, third edition, revised (DSM-III-R)23 and gave written informed consent before entry. Exclusion criteria were participation in other trials, concomitant psychotherapy, pregnancy or breast feeding, inadequate contraception, dementia, alcohol or drug dependence, concomitant serious medical condition, hypersensitivity to agnus castus, fever, pituitary disease, and concomitant use of sex hormones except oral contraceptives for which the doses were kept unchanged.
Diagnostic criteria for the premenstrual syndrome
A: In most menstrual cycles in the past year the symptoms listed under (B) occurred during the last week of the luteal phase and disappeared again a few days after onset of the follicular phase. In menstruating women this phase corresponds to the week before and a few days after the start of menstruation.
B: At least four of the following symptoms must be present in the late luteal phase of most cycles, with at least one symptom being from groups 1, 2, 3, or 4.1 Clearly unstable mood (for example, sudden sadness)2 Clear and persistent irritability or anger3 Clear anxiety, nervous tension, or feeling of being overwrought4 Clearly depressive mood, feeling of hopelessness, or reduction in self  esteem5 Reduced interest in activities such as work, family, friends, hobbies6 Rapid tiring and clear lack of energy7 Subjective feeling of not being able to concentrate8 Clear change in eating behaviour, such as increased appetite or craving  for sweet foods9 Sleep disorders such as too much sleep or sleeplessness10 Other physical symptoms such as tender breasts, feeling of bloating, headache, joint or muscle pain, weight gain
C: The symptoms are such that they are invariably noticeable and create difficulties in the normal course of daily life.
D: The symptoms are not merely an aggravated expression of the symptoms of other diseases such as depression.
Baseline assessment was at the start of the first cycle. Women's self assessment at baseline consisted of the combined scores of the following six symptoms relative to their previous three cycles: irritability, mood alteration, anger, headache, other menstrual symptoms (including bloating), breast fullness. Patients also underwent medical examination, laboratory tests (haematology, biochemistry, pregnancy test), and evaluation of clinical global impression (item 1—severity of condition).24 A visit at the start of the second cycle was allowed but not encouraged so as to minimise the chances of closer contacts with the doctor influencing the condition. A visit at the end of the third cycle (end point) was mandatory. Women then underwent full medical examination, laboratory tests (haematology, biochemistry), self assessment, clinical global impression, compliance checks, and adverse events monitoring.
Statistics, assignment, and analysis
All data were processed and analysed by the department of medical information technology at the University of Giessen. Randomisation was provided centrally in blocks of four. The main efficacy variable prospectively sought in the protocol was change from baseline to end point in the combined scores of the six self assessment items (irritability, mood alteration, anger, headache, other menstrual symptoms including bloating, and breast fullness). Women rated each item using a visual analogue scale25 validated for the assessment of the premenstrual syndrome, ranging from 0 (no symptoms) to 10 (unbearable), measured in millimetres on the linear scale. We chose the scale because it was validated and also because it correlates closely with other more complex tools and is a rapid and straightforward assessment of effect for use in community practice.21,25,26 Secondary variables were clinical global impression items 1 (severity of condition), 2 (global improvement or deterioration), and 3 (overall treatment assessment, risk or benefit) and responder rate, defined as [gt-or-equal, slanted]50% reduction in self assessed symptoms from baseline.
Our working hypothesis was that active medication is superior to placebo. We defined the intention to treat population as all randomised women who had at least one baseline value and one value after baseline and took any medication. Secondary variables were evaluated descriptively, according to Abt.27 We calculated means, SD, medians, 95% confidence intervals, minima-maxima, and absolute and relative frequencies. We calculated that a difference in mean values of 12 points and 2.5-fold SD would be clinically meaningful.25 The expected withdrawal rate was 10%. We calculated that a sample size of 80 per group would give a statistical power of 80%.28
Women's characteristics and flow through study
A total of 178 women were initially screened and randomised, of whom 170 had at least one baseline and one post-baseline value recorded (intention to treat population, figure). Characteristics at entry were balanced between the two groups (table (table1).1). Twenty three women (13%) were taking oral contraceptives (11 in the active group).
Table 1
Table 1
 Characteristics of 170 women at entry into study of agnus castus extract as treatment for the premenstrual symdrome (active treatment n=86; placebo n=84)
Efficacy results
Table Table22 shows the results at the end of the treatment period (three cycles). Analysis of the main efficacy variable (difference from baseline to end point between the two groups in self assessed symptoms) rejected the null hypothesis of the two treatments being equal. Patients who received agnus castus had a significant improvement in combined symptoms compared with those on placebo. The self assessment scores were corroborated by the physicians' own evaluation of all three items of the clinical global impression scale. Five of the six self assessment items indicated significant superiority for agnus castus (irritability, mood alteration, anger, headache, and breast fullness), other symptoms including bloating being unaffected by treatment. The responder rate was also favourable for the treated group relative to placebo (52% v 24%, respectively). Subgroup analyses that excluded women taking oral contraceptives and included the eight women who were screened but did not have any post-baseline values (assigned mean of combined groups) did not alter the results.
Table 2
Table 2
 Results at end point (end of three consecutive cycles) in 170 women with the premenstrual syndrome (active treatment n=86; placebo n=84)
Safety results
There were few adverse events (table (table3).3). Because of the low incidence of events we could not ascertain the commonest events related to agnus castus, despite the large sample sizes of the two groups. One woman withdrew because of pregnancy (placebo group) 55 days into the trial.
Table 3
Table 3
Adverse events and withdrawals from treatment
We have shown that agnus castus (Ze 440 extract tablets) is an effective treatment for women with the premenstrual syndrome. Treatment of this condition is a challenge for doctors, who most often treat these women in the community.2,8,2022 Although the condition tends to be mild to moderate, the effects on women can be debilitating.3 We planned the study with an open minded approach to the efficacy of agnus castus. Although other investigators used active comparators,21 we set out to evaluate whether or not this herbal treatment had any relevant effect on the condition. By choosing placebo rather than an active control and by informing patients of the likelihood of receiving placebo we reduced the chances of any psychological influence that an active control would have on the two groups. We reduced the clinic visits to a minimum to allow as little influence as possible from the reassurance that sometimes can be gained from frequent medical check ups. Careful screening of the women resulted in relatively few losses to follow up, which can be a problem in studies of this condition.
We chose the duration of treatment of three cycles to overcome the variability of the symptoms over time, and we set the diagnosis strictly according to established criteria. The instruments of assessment were robust and validated, and all participating physicians underwent prior training with the scales so the results were consistent across the investigating clinics (no centre effect).
What is already known on this topic
Women with the premenstrual syndrome are usually seen primary care and are a therapeutic challenge to general practitioners
Treatment of the causes is often impossible, and current treatment of the full range of symptoms is inadequate
What this study adds
Agnus castus is effective in the treatment of the premenstrual syndrome
The effects were confirmed by women's self assessment and by the doctors' evaluation
Over half the women had a 50% or greater improvement in their symptoms
Patient acceptance was high and side effects were few and mild
Patient acceptance is crucial in the treatment of this condition. The effects of agnus castus were clear to both the women and physicians. We have no data on the progress of symptoms after cessation of treatment, but other researchers have shown that though the effects of treatment gradually decrease over time, they are still felt for as long as three cycles after treatment (Berger et al, personal communication).
Tolerability of agnus castus was good in this study. Although herbal treatments are sometimes misguidedly considered to be completely safe, we did not identify any event related to treatment that could be considered prevalent in this population. In this regard, the fact that patients were aware of the chances of receiving either a herbal or placebo tablet may have played a part in the low incidence of reported events.
Conclusions
Agnus castus is a well tolerated and effective for the treatment for the premenstrual syndrome, the effects being confirmed by physicians and patients alike. The effects are detected in most main symptoms of the syndrome. This herbal remedy ought to be considered a therapeutic option in women in whom a causal origin for this syndrome cannot be established.
Figure
Figure
Flow of participants through study
Footnotes
Funding: Zeller AG, CH-8590, Switzerland supplied the study medication and sponsored the study through the Clinical Research Organisation Praxis Klinische Arzneimittelforschung, Polheim, Germany.
Competing interests: None declared.
1. Chuong CJ, Coulam CB. Current views and the beta-endorphin hypothesis. In: Gies LH, Kase NG, Berkowith C, editors. The premenstrual syndromes. New York: Churchill Livingstone; 1988. pp. 75–95.
2. Peters-Welte C, Albrecht M. Regeltempostörungen und PMS. Vitex agnus castus in einer Anwendungsbeobachtung. TW Gynäkologie. 1994;7:49–52.
3. Küpper C, Loch E-G. Prämenstruelles Syndrom. Deutsche Apotheker Zeitung. 1996;136:23–29.
4. Sondheimer S J. Etiology of premenstrual syndrome. In: Smith S, Schiff I, editors. Modern management of premenstrual syndrome. New York: Norton Medical Books; 1994. pp. 46–54.
5. Brickell C, editor. Royal Horticultural Society encyclopaedia of plants and flowers. London: Dorling Kindersley; 1989.
6. Du Mee C. Vitex agnus castus. Aust J Med Herbalism. 1993;5:63–65.
7. Hobbs C. The chaste tree: Vitex agnus castus. Pharm History. 1991;23:19–24. [PubMed]
8. Milewicz A, Gejdel E, Sworen H, Sienkiewicz K, Jedrzejak J, Teucher T, et al. Vitex agnus castus—Extrakt zur Behandlung von Regeltempoanomalien infolge latenter Hyperprolaktinämie [Vitex agnus castus extract in the treatment of luteal phase defects due to latent hyperprolactinemia. Results of a randomized placebo-controlled double-blind study] Drug Res. 1993;43:752–756. [PubMed]
9. Sliutz G, Speiser P, Schultz AM, Spona J, Zeillinger R. Agnus castus extracts inhibit prolactin secretion of rat pituitary cells. Hormone Metab Res. 1993;25:253–255. [PubMed]
10. Winterhoff H, Gorkow C, Behr B. Die Hemmung der Laktation bei Ratten als indirekter Beweis für die Senkung von Prolaktin durch Agnus castus. Z Phytotherapie. 1991;12:175–179.
11. Wuttke W, Gorkow S, Jarry H. Dopaminergic compounds in Vitex agnus castus. In: Loew D, Rietbrock N, editors. Phytopharmaka in Forschung und klinischer Anwendung. Darmstadt: Steinkopff, Verlag; 1995. pp. 81–89.
12. Jarry H, Leonhardt S, Gorkow C, Wuttke W. In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: direct evidence for a dopaminergic principle by the dopamine receptor assay. Exp Clin Endocrinol. 1994;102:448–454. [PubMed]
13. Merz PG, Gorkow C, Schrödter A, Rietbrock S, Sieder C, Loew D, et al. The effects of a special Agnus castus extract (BP 1095E1) on prolactin secretion in healthy male subjects. Exp Clin Endocrinol Diabetes. 1996;104:447–453. [PubMed]
14. Berger D, Burkard W, Schaffner W, Meier B. Rezeptorbindungsstudien mit daraus isolierten Substanzen. In: Meier B, Hoberg E, eds. Agni-casti-fructus—Neue Erkenntnisse zur Qualität und Wirksamkeit; Z Phytotherapie. 1999;20:140–158.
15. Carroll BJ, Steiner M. The psychobiology of premenstrual dysphoria: the role of prolactin. Psychoneuroendocrinol. 1978;3:171–180. [PubMed]
16. Brugisser R, Burkard W, Simmen U, Schaffner W. Untersuchungen an Opioid-Rezeptoren mit Vitex agnus-castus L. In: Meier B, Hoberg E, eds. Agni-casti-fructus—Neue Erkenntnisse zur Qualität und Wirksamkeit. Z Phytotherapie. 1999;20:140–158.
17. Samochowiec L, Glaesmer R, Samochowiec J. Einfluss von Möchspfeffer auf die Konzentration von beta-Endorphin im Serum weiblicher Ratten. Ärztezeitschr Naturheilverfahren. 1998;39:213–215.
18. Medina JH, Viola H, Wolfman C, Marder M, Wasowski C, Calvo D, et al. Neuroactive flavonoids: new ligands for the benzodiazepine receptors. Phytomedicine. 1998;5:235–243. [PubMed]
19. Shiah IS, Yatham LN. GABA function in mood disorders: an update and critical review. Life Sciences. 1998;63:1289–1303. [PubMed]
20. Jarry H, Leonhardt S, Wuttke W, Behr B, Gorkow C. Agnus castus als dopaminerges Wirkungsprinzip in Mastodynon N. Z Phytotherapie. 1991;12:77–82.
21. Lauritzen C, Reuter HD, Repges R, Böhnert KJ, Schmidt U. Treatment of premenstrual tension syndrome with Vitex agnus castus—controlled, double-blind study versus pyridoxine. Phytomedicine. 1997;4:183–189. [PubMed]
22. Roeder D. Therapie von Zyklusstörungen mit Vitex agnus-castus. Z Phytotherapie 1994;15:155-9.
23. American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 3rd ed, rev. Washington, DC: American Psychiatric Association; 1987.
24. National Institute of Mental Health. 028 CGI clinical global impressions. In: Guy W, ed. ECDEU assessment for psychopharmacology. Rev ed. Rockville, Maryland, 1976:217-22.
25. Casper RF, Powell AM. Premenstrual syndrome: documentation by a linear analog scale compared with two descriptive scales. Am J Obstet Gynecol. 1986;155:862–867. [PubMed]
26. Steiner M, Haskett RF, Carroll BJ. Premenstrual tension syndrome: the development of research diagnostic criteria and new rating scales. Acta Psychiatr Scand. 1980;62:177–190. [PubMed]
27. Abt K. Descriptive data analysis: a concept between confirmatory and exploratory data analysis. Meth Inform. 1987;26:77–88. [PubMed]
28. Machin D, Campbell MJ. Statistical tables for the design of clinical trials. Oxford: Blackwell Scientific Publications; 1987. pp. 81–83.
Articles from BMJ : British Medical Journal are provided here courtesy of
BMJ Group